Marshall Wace, LLP Chroma Dex Corp. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.44 - $4.32 $50,207 - $88,892	20,577 New	20,577 $56,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.19 $70,288 - $104,007	-47,492 Reduced 57.85%	34,600 $52,000
Q3 2022 Nov 14, 2022	BUY	$1.19 - $2.06 $38,842 - $67,240	32,641 Added 66.01%	82,092 $101,000
Q2 2022 Aug 15, 2022	SELL	$1.59 - $2.7 $45,505 - $77,274	-28,620 Reduced 36.66%	49,451 $83,000
Q1 2022 May 16, 2022	BUY	$2.02 - $3.92 $157,703 - $306,038	78,071 New	78,071 $193,000
Q4 2021 Feb 14, 2022	SELL	$3.74 - $6.7 $332,366 - $595,415	-88,868 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.05 - $10.41 $61,347 - $105,557	10,140 Added 12.88%	88,868 $557,000
Q2 2021 Aug 13, 2021	SELL	$6.66 - $10.92 $1.23 Million - $2.01 Million	-184,114 Reduced 70.05%	78,728 $776,000
Q1 2021 May 17, 2021	BUY	$4.59 - $18.74 $1.21 Million - $4.93 Million	262,842 New	262,842 $2.46 Million

17.2M

66.7K

8.2K

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $510M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.